Shares of Sun Pharma Advanced Research Company Ltd (SPARC) plunged nearly 20% on Wednesday on the NSE, after the company ...

SPARC tumbled 19 percent after Phase 2 trials of its psoriasis drug SCD-044 failed to meet primary endpoints. The company ...

8% of patients maintained that the ongoing war had affected the quality of the treatment they are receiving for psoriasis.

SPARC share price plunged 20% following poor Phase 2 trial outcomes for SCD-044. The stock peaked at ₹186 but fell to ₹156.50 during trading on the BSE.

The storm cast this already virtually soundless vista into absolute silence—exactly what I’d come to Iceland with Tom ...

Sun Pharma shares are in focus after the company halted its Phase II clinical trial for SCD-044. Meanwhile, Zydus ...

Sun Pharmaceutical , India's largest drugmaker by revenue, reported a bigger adjusted quarterly profit on Thursday, driven by ...

NOW the sun is out, your SPF should be too. Did you know we are recommended to use two shot glasses worth of suncream to cover our body? It might seem excessive, but no patch should be left ...

The bacteria that live on your skin could be playing a role in protecting you from the sun's harmful UV rays, scientists have ...

Dry brushing your skin can help you exfoliate and lead to smoother skin. As long as you don't have any health conditions that ...

She has had many relapses since, but one in particular was severe. Five years ago she couldn’t move off her right side ...

Skin bacteria may protect against UV damage by metabolizing a sun-induced molecule, influencing immune responses.